Across TCGA pan-cancer cohorts, MZT1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MZT1 data layer compared with 22 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher MZT1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MZT1 expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

HNSC, LSCC, and UCEC are the cancer types where MZT1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	III,IV	0.773	0.471	.001	13	view →
LSCC	DFS	Tertile	III,IV	0.380	1.000	.019	13	view →
UCEC	OS	Median	II,III,IV	0.590	1.000	.007	12	view →
CCRCC	DFS	Median	III,IV	1.000	0.451	.032	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: MZT1 tumor-vs-normal RNA expression · all MZT1 data types